Dergiler / The Anatolian Journal of Cardiology / 2020 / Cilt: 23 - Sayı: 1

In-stent restenosis of drug-eluting stents in patients with diabetes mellitus: Clinical presentation, angiographic features, and outcomes

Sayfa
28–34
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Age, MI presentation, CKD, and not DM were predictors of poor outcomes following DES-ISR. (Anatol J Cardiol 2020; 23: 28-34)

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Diabetes mellitus (DM) is a risk factor for developing in-stent restenosis (ISR) following percutaneous coronary intervention (PCI).This study aimed to examine the presentation and outcomes of drug-eluting stent (DES) ISR in diabetics.Methods: This retrospective study included consecutive patients with clinical DES-ISR, who were hospitalized between January 2013 and December 2017 and who were grouped based on the presence or absence of DM.
📊
Temel Bulgular & Veri:Clinical, angiographic features and 1-year outcomes [compositeof death, myocardial infarction (MI), and repeat-target lesion revascularization] were compared.Results: Baseline characteristics of the DM group (n=109) were comparable to the non-DM group (n=82), except for the higher prevalence ofhypertension and dyslipidemia in the former (60.6% vs. 46.3%, p=0.050; 74.4% vs. 57.8%, p=0.034, respectively).
💡
Sonuç & Katkı:Age, MI presentation, CKD, and not DM were predictors of poor outcomes following DES-ISR. (Anatol J Cardiol 2020; 23: 28-34)
🔬Tür:Araştırma Makalesi
📍Kapsam:2013 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: Diabetes mellitus (DM) is a risk factor for developing in-stent restenosis (ISR) following percutaneous coronary intervention (PCI).This study aimed to examine the presentation and outcomes of drug-eluting stent (DES) ISR in diabetics.Methods: This retrospective study included consecutive patients with clinical DES-ISR, who were hospitalized between January 2013 and December 2017 and who were grouped based on the presence or absence of DM. Clinical, angiographic features and 1-year outcomes [compositeof death, myocardial infarction (MI), and repeat-target lesion revascularization] were compared.Results: Baseline characteristics of the DM group (n=109) were comparable to the non-DM group (n=82), except for the higher prevalence ofhypertension and dyslipidemia in the former (60.6% vs. 46.3%, p=0.050; 74.4% vs. 57.8%, p=0.034, respectively). Clinical presentation was similarin both groups [acute coronary syndrome (ACS): 62.4% vs. 61%, p=0.843; MI: 34.9% vs. 34.1%, p=0.918). Diabetics had a higher prevalence ofstent-edge restenosis (20.3% vs. 9.2%, p=0.019). The treatment strategy was similar in both groups with 52.3% in the DM group and 57.3% inthe non-DM group undergoing PCI (p=0.513). One-year outcomes of the DM group were not different from those of the non-DM group (14.7%vs. 17.1%, p=0.683). Age [hazard ratio (HR), 1.05; 95% confidence interval (CI), 1.01–1.10; p=0.017], MI presentation (HR, 2.34; 95% CI, 1.14–4.80;p=0.020), and chronic kidney disease (CKD: HR, 2.82; 95% CI, 1.21–6.58; p=0.016) were predictors of poor outcomes.Conclusion: Stent-edge restenosis is more common in diabetics. Clinical presentation and 1-year outcomes following DES-ISR are similar in diabetics and non-diabetics. Age, MI presentation, CKD, and not DM were predictors of poor outcomes following DES-ISR. (Anatol J Cardiol 2020; 23: 28-34)

🔖

Bu Makaleye Atıf Yap

PARAMASIVAM, G., DEVASIA, T., JAYARAM, A., RAO, M. S., RAZAK, T. A., VIJAYVERGIYA, R., NAYAK, K. (2020). In-stent restenosis of drug-eluting stents in patients with diabetes mellitus: Clinical presentation, angiographic features, and outcomes. The Anatolian Journal of Cardiology, Cilt: 23 - Sayı: 1, 28–34. https://ajindex.com/articles/366671

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (10)

  1. Camenzind E. Treatment of in-stent restenosis--back to the future? N Engl J Med 2006; 355: 2149-51
  2. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007; 370: 937-48
  3. Iijima R, Ndrepepa G, Mehilli J, Markwardt C, Bruskina O, Pache J, et al. Impact of diabetes mellitus on long-term outcomes in the drugeluting stent era. Am Heart J 2007; 154: 688-93
  4. Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schömig A, et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ 2008; 337: a1331
  5. Billinger M, Räber L, Hitz S, Stefanini GG, Pilgrim T, Stettler C, et al. Long-term clinical and angiographic outcomes of diabetic patients after revascularization with early generation drug-eluting stents. Am Heart J 2012; 163: 876-86
  6. Tada T, Kimura T, Morimoto T, Ono K, Furukawa Y, Nakagawa Y, et al. Comparison of three-year clinical outcomes after sirolimus-eluting stent implantation among insulin-treated diabetic, non-insulintreated diabetic, and non-diabetic patients from j-Cypher registry. Am J Cardiol 2011; 107: 1155-62
  7. Kedhi E, Genereux P, Palmerini T, McAndrew TC, Parise H, Mehran R, et al. Impact of coronary lesion complexity on drug-eluting stent outcomes in patients with and without diabetes mellitus: analysis from 18 pooled randomized trials. J Am Coll Cardiol 2014; 63: 2111-88. Zhao L, Zhu W, Zhang X, He D, Guo C. Effect of diabetes mellitus on long-term outcomes after repeat drug-eluting stent implantation for in-stent restenosis. BMC Cardiovasc Disord 2017; 17: 16
  8. Byrne RA, Cassese S, Windisch T, King LA, Joner M, Tada T, et al. Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis; evidence in support of drug resistance: insights from the ISAR-DESIRE and ISAR-DESIRE 2 trials. EuroIntervention 2013; 9: 797-802
  9. Xu B, Gao R, Wang J, Yang Y, Chen S, Liu B, et al. A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent instent restenosis: results from the PEPCAD China ISR trial. JACC Cardiovasc Interv 2014; 7: 204-11
  10. Alfonso F, Perez-Vizcayno MJ, Cardenas A, Garcia del Blanco B, Garcia-Touchard A, Lopez-Minguez JR, et al. A Prospective Randomized Trial of Drug-Eluting Balloons